Molecule

Drug Groups

approved

Description

A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [PubChem]

Indication

For prophylaxis and treatment of bacterial infections.

Pharmacology

Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.

Affected Organisms

Biotransformation

No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.

Half Life

In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged

Protein Binding

Cefotetan is 88% plasma protein bound.

Elimination

No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.

Distribution

* 10.4 L [elderly patients (greater than 65 years) with normal renal function]
* 10.3 L [healthy volunteers (aged 25 to 28 years)]

Clearance

* 1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)]
* 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]

External Links